Supraventricular arrhythmia in pregnancy

Karishma P Ramlakhão, Robert M Kauling, Nicole Schenkelaars, Dolf Segers, Sing-Chien Yap, Martijn C Post, Jérôme Cornette, Jolien W Roos-Hesselin

ABSTRACT
The physiological changes during pregnancy predispose a woman for the development of new-onset or recurrent arrhythmia. Supraventricular arrhythmia is the most common form of arrhythmia during pregnancy and, although often benign in nature, can be concerning. We describe three complex cases of supraventricular arrhythmia during pregnancy and review the currently available literature on the subject. In pregnancies complicated by arrhythmia, a plan for follow-up and both maternal and fetal monitoring during pregnancy, delivery and post partum should be made in a multidisciplinary team. Diagnostic modalities should be used as in non-pregnant women if there is an indication. All antiarrhythmic drugs cross the placenta, but when necessary, medical treatment should be used with consideration to the fetus and the mother’s altered pharmacodynamics and kinetics. Electrical cardioversion is safe during pregnancy, and electrophysiological study and catheter ablation can be performed in selected patients, preferably with zero-fluoroscopy technique. Sometimes, delivering the fetus (if viable) is the best therapeutic option. In this review, we provide a framework for the workup and clinical management of supraventricular arrhythmias in pregnant women, including cardiac, obstetric and neonatal perspectives.

INTRODUCTION
Anatomical, haemodynamic and hormonal changes in the maternal physiology make pregnancy a high-risk period for the occurrence of new-onset arrhythmia, or the recurrence of pre-existing arrhythmia. The maternal intravascular volume expands up to 45% throughout pregnancy, to compensate for a fall in systemic vascular resistance that facilitates the formation of the uteroplacental circulation. The volume expansion causes atrial and ventricular stretch, which in combination with a physiologically increased heart rate and contractility, increased sympathetic activity and altered catecholamine sensitivity creates an arrhythmogenic state. Arrhythmia risk peaks in the third trimester. Maternal risk factors are previous arrhythmia, advanced maternal age, African ancestry and congenital heart disease, in which surgical scars and aberrant cardiac anatomy compound the situation. Data on the prevalence of arrhythmia during pregnancy are scarce and conflicting, and lack clarity because complaints of palpitations are common and predominantly benign. Arrhythmia was observed in 68 per 100 000 pregnancy-related hospitalisations, which probably underestimates the total prevalence considering the additional cases of arrhythmias without hospitalisation.

Supraventricular arrhythmias are more common than ventricular arrhythmias and will be the focus of this review.

Atrial fibrillation or flutter (AF, 31–59 per 100 000 pregnancies) is the most frequently reported arrhythmia in pregnancy, with a growing prevalence in the past two decades that may be partly explained by the increasing maternal age. Non-AF supraventricular tachycardia (SVT) is reported in 22–33 per 100 000 pregnancies, including atrioventricular nodal re-entry tachycardia (AV(N)RT) and atrial tachycardia. Although most arrhythmias are benign, they are associated with increased maternal mortality (OR 13 for AF and OR 6 for SVT). Appropriate workup and multidisciplinary management are therefore important, but the literature to guide clinical decisions is scarce. In this review, we describe three complex cases seen in a tertiary referral centre and provide a step-by-step guide for the management of supraventricular arrhythmias during pregnancy.

CASE SERIES
Case 1
A primigravid woman aged 34 years presented at the emergency department of an affiliated secondary care centre with complaints of palpitations at 37 weeks of gestation. She previously had an uneventful pregnancy; had no relevant history of cardiac disease, but was known with Crohn’s disease and hypothyroidism. Her ECG showed a regular SVT of 220 bpm. A short RP narrow complex tachycardia was observed, consistent with AVNRT or atrioventricular re-entry tachycardia (AV(R)RT) (figure 1). She showed no signs of congestion. The patient was admitted and repeatedly treated with adenosine intravenously, with only temporary conversion to sinus rhythm. A cumulative dosage of 7.5 mg of metoprolol intravenously and 50 mg metoprolol orally were given next, without success. After 4 hours of sustained tachycardia, intravenous verapamil was administered to a total amount of 10 mg. The heart rate decreased to 180 bpm, but stable sinus rhythm was not achieved. The patient remained haemodynamically stable and the fetal heart rate pattern on the cardiotocogram (CTG) was reassuring.

In consultation with our tertiary care centre, we decided to eliminate the most-likely trigger of the tachycardia: the pregnancy itself. An uneventful emergency caesarean section was performed, six-and-a-half hours after the patient’s first presentation. After induction of general anaesthesia, the patient spontaneously converted and remained in sinus rhythm. A son of 3206 g (67th percentile) was born with initially low Apgar scores of 4/5/8...
but the therapeutic anticoagulation that is required after ECV for the associated thromboembolic risk. One year after delivery, she had a new episode of AF which could be terminated by ECV. An exercise echocardiogram was performed and showed an increase in the mean gradient of the mitral valve prosthesis from 9 mm Hg at rest to 16 mm Hg during exercise. After discussion in the multidisciplinary heart team, she underwent a re-operation and a mechanical mitral valve prosthesis (considering her family was complete) was inserted successfully. No complications occurred during hospitalisation and at latest follow-up, 3 months after surgery.

Case 3
A primigravid woman aged 38 years presented at 16 weeks of gestation at a secondary hospital with palpitations that had increased in intensity during pregnancy. She had no history of cardiac disease. She was diagnosed with an AV(N)RT and treated with metoprolol 12.5 mg twice daily without sufficient effect, after which she was referred to our centre. Here, the ECG showed a regular SVT of 205 bpm with an intermediate axis and a narrow QRS complex (figure 3A). A mid-RP narrow complex tachycardia was observed, consistent with AVNRT, AVRT or less likely atrial tachycardia. The arrhythmia terminated spontaneously, but afterwards many recurrences were observed, at 1/5/10 min, based on transient respiratory insufficiency due to the anaesthesia. After 4 days in the neonatology ward, he was discharged in good health. In the mother, a hyperthyroidism due to oversupplementation of her levothyroxine was diagnosed and treated accordingly. One year later, the patient was seen for preconception counselling and although no recurrence of the AV(N)RT had occurred, an electrophysiological (EP) study was performed. An orthodromic AVRT with a left posteroseptal accessory pathway could be induced and was successfully ablated.

Case 2
A woman aged 35 years, gravida 2 para 1, first presented in a secondary hospital with AF at 12 weeks of gestation. She was known with Marfan syndrome and had undergone an ascending aorta replacement and implantation of a mitral bioprosthesis (for regurgitation) in 2004, followed by a bioprosthesis replacement in 2014. Her current AF was treated with a trans-oesophageal echo-guided electrocardioversion (ECV) and Coumadin, after which she was referred to our centre for further follow-up. At 20 weeks of gestation, a transthoracic echocardiogram showed normal systolic function of the left ventricle, but a moderate stenosis of the mitral valve prosthesis with a mean gradient of 7 mm Hg (figure 2A). A recent prepregnancy MRI of the thoracic aorta showed normal aortic dimensions and good status of her ascending aorta graft, so imaging was not repeated. Our multidisciplinary pregnancy heart team considered her to be in class II–III following the modified WHO (mWHO) maternal cardiovascular risk classification. An exercise echocardiogram was performed and showed an increase of the mean gradient of the mitral valve prosthesis to 10 mm Hg, with normal right ventricular pressure (figure 2C). Holter monitoring for 48 hours showed no recurrence of AF, but considering the progressive mitral valve prosthesis stenosis and markedly increased size of the left atrium, we decided to restart Coumadin for the associated thromboembolic risk. One year after delivery, she underwent a re-operation and a mechanical mitral valve prosthesis (considering her family was complete) was inserted successfully. No complications occurred during hospitalisation and at latest follow-up, 3 months after surgery.

Figure 1  ECG of a woman aged 34 years presenting at 37 weeks of gestation with a regular supraventricular tachycardia of 220 bpm with a retrograde P wave, suggestive of an atrioventricular (nodal) re-entry tachycardia. Hyperthyroidism and an atrioventricular re-entry tachycardia with concealed bypass were later discovered.
Figure 2 Transthoracic echocardiogram and ECG of a woman aged 35 years with Marfan syndrome and a mitral valve bioprosthesis, presenting at 14 weeks of gestation with atrial fibrillation. (A) Transthoracic echo at 20 weeks of gestation showing parasternal and apical view of the bioprosthesis. Continuous wave Doppler showing a mean peak gradient of 7 mm Hg. (B) ECG showing recurrent atrial fibrillation with rapid ventricular response at 37 weeks of gestation. (C) Continuous wave Doppler at 2 months post partum, showing worsening mitral stenosis with a mean PG of 10 mm Hg of the prosthetic valve and tricuspid regurgitation velocity of 2.4 m/s.
treated with analgesia and colchicine. Unfortunately, the procedure was complicated by pericardial congestion. An echocardiogram showed that there was no structural heart disease.11 Rhythm-surveillance level 1 was recommended during delivery (table 1). An EP study with ablation was discussed, but we decided to first pursue pharmacological treatment and only perform an ablation in case of refractory complaints. Verapamil 120 mg once daily replaced the metoprolol, and she was advised to avoid excessive exertion. The dosage was gradually increased to 120 mg three times daily, with an acceptable but incomplete result on the frequency and intensity of her complaints. The fetal status and growth were monitored regularly in the obstetric outpatient clinic with CTG and fetal ultrasound, and remained reassuring. Labour was induced at 37 weeks of gestation because of the persisting palpitations after delivery. A left lateral incision was used, and the child was the most important step and best option in this patient’s treatment, considering her pregnancy was at term gestational age.

**DISCUSSION**

We have described three cases of supraventricular arrhythmia during pregnancy where different forms of intervention were necessary. Figure 5 presents a step-by-step guide for the diagnosis and management of supraventricular arrhythmia in pregnancy.

**Table 1** Recommended surveillance levels during delivery in women with supraventricular arrhythmia

| Indication               | Low risk*               | Surveillance during delivery | Medium risk               |
|--------------------------|-------------------------|-----------------------------|---------------------------|
| PSVT, AF, Wolff-Parkinson-White syndrome | Consult multidisciplinary team including arrhythmologists at central specialist centre | Consultation with multidisciplinary team including arrhythmologists at specialised centre |
| PSVT, paroxysmal supraventricular tachycardia, SVT | Mode and location of delivery on obstetric indication | Mode and location of delivery on obstetric indication |
| SVT, supraventricular tachycardia | Monitor cardiac rhythm (3-lead ECG) | Monitor cardiac rhythm (3-lead ECG) |
| SVT, supraventricular tachycardia | Intravenous line | Intravenous line |
| SVT, supraventricular tachycardia | Prepare for intravenous administration of adenosine | Prepare for intravenous administration of adenosine |
| SVT, supraventricular tachycardia | External cardioverter defibrillator at site | External cardioverter defibrillator at site |

Based on the 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy.11

*The risk of arrhythmia with haemodynamic compromise during delivery; the high-risk category includes ventricular arrhythmia only and is therefore excluded in the table.

AF, atrial fibrillation; ESC, European Society of Cardiology; PSVT, paroxysmal supraventricular tachycardia; SVT, supraventricular tachycardia.

provoked by light physical activity. There were no signs of congestion. An echocardiogram showed that there was no structural heart disease.

According to the ESC guidelines, our multidisciplinary pregnancy heart team classified her as mWHO II, as all supraventricular arrhythmia without underlying structural heart disease.11 Rhythm-surveillance level 1 was recommended during delivery (table 1). An EP study with ablation was discussed, but we decided to first pursue pharmacological treatment and only perform an ablation in case of refractory complaints. Verapamil 120 mg once daily replaced the metoprolol, and she was advised to avoid excessive exertion. The dosage was gradually increased to 120 mg three times daily, with an acceptable but incomplete result on the frequency and intensity of her complaints. The fetal status and growth were monitored regularly in the obstetric outpatient clinic with CTG and fetal ultrasound, and remained reassuring. Labour was induced at 37 weeks of gestation because of the persisting palpitations after delivery. A left lateral incision was used, and the child was the most important step and best option in this patient’s treatment, considering her pregnancy was at term gestational age.

**Case 1**

Although AV(N)RT in pregnancy are usually well tolerated, they can become symptomatic or cause haemodynamic instability, especially in the presence of underlying heart disease. After primary examination with appropriate workup, vagal manoeuvres, pharmacological treatment with adenosine intravenously are the first choice of treatment in the acute setting in haemodynamically stable patients (figure 5). In case of insufficient effect or haemodynamic compromise, ECV is indicated, especially as in pregnancy some medication may be harmful.12

**Drugs**

All antiarrhythmic drugs (AAD) cross the placenta, although data on fetal toxicity are often limited. If possible, drug therapy may be avoided or postponed until after the first trimester, in which the teratogenic risk is highest, but therapy can be necessary and justified in persisting arrhythmias.12 Due to the altered maternal pharmacodynamics and kinetics, the required drug dosage may be either lower or higher (eg, digoxin, due to increased clearance and volume of distribution) than in non-pregnant women. Table 2 lists the safety during pregnancy and lactation of commonly used drugs for rhythm and rate control and anticoagulation.

In case 1, adenosine and verapamil were used, both of which prolong the effective refractory period of the AV node and have a success rate of 90% in terminating acute attacks.13 Alternatively, digoxin or beta-blockers could be used to terminate or supress AV(N)RT. Adenosine can be safely administered in the same dosage as in non-pregnant patients. There are few data on verapamil or diltiazem, but no teratogenicity or maternal side effects during pregnancy are reported.14 Caution is warranted when combining class 1C or 1A because of potentially deleterious negative inotropic and chronotropic effects on mother and fetus.

In case 1, sinus rhythm was established only after the delivery, which shows the crucial role that pregnancy physiology has in provoking the new onset or (frequent) recurrence of arrhythmia. The initial and additional assessment should also consider other triggers, such as anaemia, stress or thyroid dysfunction (figure 5). In AV(N)RT, there are usually no underlying cardiac abnormalities. In case 1, both the hyperthyroidism and the concealed bypass contributed to the arrhythmia. However, the delivery of the child was the most important step and best option in this patient’s treatment, considering her pregnancy was at term gestational age.

**Delivery and post partum**

Neurohormonal changes and pain during labour stimulate the sympathetic nervous system, which increases the heart rate and contractility.15 The cardiac output is further increased by exertion and fluid shifts. The timing and mode of delivery and surveillance level should be individualised in a delivery plan by a multidisciplinary pregnancy heart team, considering cardiac, obstetric and fetal factors. The ESC guidelines consider paroxysmal SVT, AF and Wolff-Parkinson-White syndrome to be low risk, and consultation of a cardiologist is the only recommendation (table 1).11 Unstable SVTs are classified as medium risk and consultation of a specialised multidisciplinary team, including arrhythmologists, is advised. The mode and location of the delivery are on obstetric indication, although continuous telemetry, intravenous access and an external cardioverter defibrillator should be available.11
Due to physiological fluid shifts or complications such as postpartum haemorrhage, haemodynamic changes in the first days post partum may trigger arrhythmia and even heart failure, especially in case of prepregnancy decreased ejection fraction or valvular disease. Monitoring by 3-lead ECG and vital functions should be continued for at least 24–48 hours after delivery for women with a medium-risk or high-risk pregnancy.16

Preconception counselling

In case 1, the patient received preconception counselling before she started her second pregnancy, and subsequently her AVRT could be ablated before she got pregnant. This illustrates the added value of preconception counselling in women with a history of arrhythmia, or an increased risk of developing it because of structural heart disease. In general, the recurrence rate during pregnancy for women with previous AF is 25%–52%8 and the incidence of AF for women with structural heart disease is 1.3%.17 The recurrence rate of SVT during pregnancy is 50%.8 However, the risk may be higher in patients with more complex cardiac disease, ranging from 0.8% in patients with an atrial septal defect to 15.6% in patients with transposition of the great arteries.18 Besides the recurrence rates, the preconception counselling should educate the patient about the symptoms suggestive of arrhythmia and what they should do in case of complaints. There might be a role for haemodynamic testing as part of preconception counselling, however, data are scarce on what kind of tests are the most informative and what the cut-off values should be to base clinical decisions on.

Figure 3 ECG and echocardiogram of a woman aged 38 years at 16 weeks of gestation, presenting with atrioventricular (nodal) re-entry tachycardia (AV(N)RT). (A) ECG of a regular supraventricular tachycardia of 205 bpm with an intermediate axis and a narrow QRS complex. A retrograde P wave was observed 120 ms behind the QRS complex, suggestive of an AV(N)RT. (B) Subcostal view of an echocardiogram after an electrophysiological (EP) study with ablation for a left lateral concealed bypass atrioventricular re-entry tachycardia, showing moderate pericardial effusion as complication of the EP study.
Contrary to other types of supraventricular arrhythmia, AF in a young woman with a structurally normal heart is uncommon and additional cardiac assessment to rule out any underlying structural heart disease is essential (figure 5). The most important risk factors are a history of AF (OR 7.1), mitral valve disease (OR 6.9) and left-sided cardiac lesions (OR 2.9). Electric cardioversion

In case of sustained supraventricular arrhythmia or haemodynamic instability, ECV is recommended as in non-pregnant women (figure 5). No deleterious effects of ECV on fetal haemodynamics are reported and the risk of inducing fetal arrhythmias or inducing premature labour is deemed very low, but it is recommended to perform CTG monitoring directly after.
Patients with moderate mitral stenosis, like in case 2, may have scores, and therapeutic anticoagulation should be considered.23 Previous stroke/transient ischemic attack (vascular disease) is also severe left atrial enlargement or spontaneous contrast, factors in this patient.

We advise low molecular weight heparin (LMWH) in a prophylactic loading dose of 1 mg/kg followed by 0.5 mg/kg every 12 hours. The patient waited for 48 hours to see if drug therapy is sufficient as treatment. Rate control should be instated and the patient could be observed for 24 hours to see if drug therapy is sufficient as treatment. The procedure was complicated by pericardial effusion and atrial fibrillation. As this complication would have been even more dramatic during pregnancy, the procedure was postponed until after delivery. The procedure was complicated by pericardiocentesis, which illustrates the risks, and therapeutic anticoagulation should be considered.13

In case 2, the delivery was postponed to allow for enough time after stopping the LMWH and waited for 48 hours to restart Coumadin post partum. Coumadin was restarted considering the combination of the congenital heart disease and pregnancy as thrombogenic risk factors in this patient.

Case 3
In case 3, a high dosage of verapamil was necessary to suppress the AVRT, of which the fetal effects are unknown. Therefore, regular follow-up was performed of the fetal heart rate and growth during pregnancy, and post partum the neonate was observed for 24 hours in the neonatology ward.

Fetal and neonatal monitoring
There are few data on the offspring risks after supraventricular arrhythmia during pregnancy. Paroxysmal SVT is associated with low birth weight (OR 1.7), but the attributable effect of the SVT versus the medication used is unclear.24 Consequently, there is no consensus on the requirements for fetal monitoring, which may depend on the type of SVT, the gestational age and the effects of the type of medication used (table 2). Beta-blockers, for example, may cause intrauterine growth restriction, which requires regular monitoring of fetal growth, and also fetal bradycardia and hypoglycaemia, which requires neonatal monitoring post partum.25

In case 3, an EP study was considered but postponed until after the delivery. The procedure was complicated by pericardial effusion that required pericardiocentesis, which illustrates the risks, as this complication would have been even more dramatic during pregnancy.

EP study and catheter ablation
EP study and ablation could be considered in highly selected patients with drug-refractory SVT.11 12 After multidisciplinary team consultation, a careful risk-benefit discussion with the

---

**Table 2** Drugs used in the treatment of arrhythmia and their safety during pregnancy and lactation

| Drug class | Drug name | Safety during pregnancy | Compatible with breast feeding? |
|------------|-----------|-------------------------|---------------------------------|
| Rhythm/Rate control | Beta-blockers | Metoprolol, propranolol, bisoprolol, atenolol | Considered safe, but may cause risk of fetal bradycardia, hypoglycaemia and intrauterine growth restriction. Atenolol: not preferable, possible teratogenicity in first trimester. | Yes; propranolol, metoprolol and labetalol are preferable |
| | Calcium-channel blockers | Verapamil, diltiazem | Probably safe, induces tocolysis and may cause maternal hypotension and subsequent fetal distress. Diltiazem: limited human data, possible teratogenicity in animals. | Yes |
| | Cardiac glycosides | Digoxin | Considered safe, preferable in treating arrhythmia. Increased renal clearance may necessitate higher dosage to maintain therapeutic levels. | Yes |
| | Antianthyrhythm drugs | Adenosine | Considered safe. | Yes |
| | | Amiodarone | Unsafe, may cause fetal thyroid disorders, but use in acute treatment may be warranted. | No |
| | Antianthyrhythm drugs | Flecainide | Commonly used in the intraterine treatment of fetal tachycardia in the second and third trimester, but safety in the first trimester is unclear due to reports of teratogenicity in animals. | Unknown |
| | | Lidocaine | Considered safe, may cause fetal bradycardia and acidosis. | Yes |
| | | Procainimide | Considered safe. | Yes |
| | | Quinidine | May cause fetal thrombocytopenia and preterm labour due to an oxytocic effect in high doses. | Yes |
| | Antianthyrhythm drugs | Sotalol | Considered safe, may cause fetal bradycardia and hypoglycaemia. | No |
| Anticoagulation | Direct oral anticoagulants | Apixaban, dabigatran | Contraindicated due to teratogenicity in animal studies and bleeding risks. | No |
| | Antiplatelet drugs | Acetylsalicylic acid, clopidogrel | Aspirin: considered safe in a low dose (<150 mg). Clopidogrel: limited human data show no harm, use for shortest duration possible. | Aspirin: yes; Clopidogrel: unknown |
| | Heparins | Low molecular weight heparin, unfractioned heparin | Safe for the fetus, but may cause maternal bleeding complications, in particular during delivery: plan dosage accordingly. | Yes |
| | Vitamin K antagonists | Acenocoumarol, fenprocoumon, warfarin | Use in the first trimester may cause embopatathy and miscarriage, use at time of delivery may cause maternal and fetal bleeding complications. | Yes |

Based on the 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy,11 Drugs in Pregnancy and Lactation31 and the FDA Pregnancy and Lactation Labelling Rule, Drugs and Lactation Database (LactMed).

ESC, European Society of Cardiology; FDA, Food and Drug Administration.

---

ECV.22 If the cardioversion must be postponed, drug therapy for rate control should be instated and the patient could be observed for 24 hours to see if drug therapy is sufficient as treatment. However, this increases the duration of maternal tachycardia and AADs may have fetal effects (table 2).

Anticoagulation
It is not clear whether the same rules for stroke-prediction risk stratification can be used as in non-pregnant patients,20 because pregnancy should be considered a prothrombotic state because of a physiological increase in clotting factors and a decrease in anticoagulant and fibrinolytic factors.15 In women with congenital heart disease underlying the arrhythmia, thromboembolic risk is increased even in those with a low CHADS2/CHA2DS2-VASc (congestive heart failure, hypertension, age, diabetes, previous stroke/transient ischemic attack (vascular disease) scores, and therapeutic anticoagulation should be considered.13

Patients with moderate mitral stenosis, like in case 2, may have an increased risk of developing intra-atrial thrombi and if there is also severe left atrial enlargement or spontaneous contrast, we advise low molecular weight heparin (LMWH) in a prophylactic dose. Careful timing of anticoagulation around the period of delivery is crucial because of the bleeding risk. In case 2, we postponed the delivery to allow for enough time after stopping the LMWH and waited for 48 hours to restart Coumadin post partum. Coumadin was restarted considering the combination of the congenital heart disease and pregnancy as thrombogenic risk factors in this patient.
CONCLUSIONS

Pregnancy creates an arrhythmogenic environment and the pregnant population is increasingly at risk of arrhythmias. Starting at the initial presentation, a multidisciplinary approach is crucial to balance maternal cardiac, obstetric and fetal considerations. In any case, optimal maternal health is a prerequisite for good fetal health, so diagnostic modalities and therapeutic options (such as electrical or chemical cardioversion) should be used where necessary and not be avoided or delayed because of the fetus. Knowledge of the physiology of pregnancy helps to predict the effects and consequences of interventions and drug therapy. A good secondary assessment for underlying causes of arrhythmia, such as structural heart disease or endocrine disorders, should not be forgotten. However, often the pregnancy itself is the most important contributor to the burden of arrhythmia, and the delivery of the child is sometimes a viable therapeutic option.

REFERENCES

1. de Haas S, Ghoossein-Doha C, van Kuik SMJ, et al. Physiological adaptation of maternal plasma volume during pregnancy: a systematic review and meta-analysis. Ultrasound Obstet Gynecol 2017;49:177–87.

2. Brodsky M, Doria R, Allen B, et al. Cardiac output and related haemodynamics during pregnancy: a series of meta-analyses. Heart 2016;102:518–26.

3. Shotton A, Oztuezga E, Mehra A, et al. Incidence of arrhythmias in normal pregnancy and relation to palpitations, dizziness, and syncpe. Am J Cardiol 1999;79:1061–4.

4. Li J-M, Nguyen C, Jglar JA, et al. Frequency and outcome of arrhythmias complicating admission during pregnancy: experience from a high-volume and ethnically-diverse obstetric service. Clin Cardiol 2008;31:538–41.

5. Tatemoto S, Niwa K, Nakazawa M, et al. Arrhythmia and conduction disturbances in patients with congenital heart disease during pregnancy: multicenter study. Circ J 2003;67:992–7.

6. Vaidya VR, Arora S, Patel N, et al. Burden of arrhythmia in pregnancy. Circulation 2017;135:619–21.

7. Silversides CK, Harris L, Haberer K, et al. Recurrence rates of arrhythmias during pregnancy in women with previous tachyarrhythmia and impact on fetal and neonatal outcomes. Am J Cardiol 2006;97:1206–12.

8. Lee M-S, Chen W, Zhang Z, et al. Atrial fibrillation and atrial flutter in pregnant Women-A population-based study. J Am Heart Assoc 2016;5:e003182.

9. Lee K-T, Chang S-H, Kuo C-F, et al. Incidence and time course of symptomatic paroxysmal supraventricular tachycardia during pregnancy: a nation-wide database study. Acta Cardiol Sin 2020;36:44–9.

10. Regitz-Zagrosek V, Roos-Hesselink JW, Bauschacq J, et al. 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J 2018;39:3165–241.

11. Brugada J, Katritsis DG, Areal E, et al. 2019 ESC guidelines for the management of patients with supraventricular tachycardiaThe Task force for the management of patients with supraventricular tachycardia of the European Society of cardiology (ESC). Eur Heart J 2020;41:655–720.

12. Goy J-I, Fromer M. Antiarrhythmic treatment of atrioventricular tachycardias. J Cardiovasc Pharmacol 1995;25:541–40.

13. Byerly WG, Hartmann A, Foster DE, et al. Verapamil in the treatment of maternal paroxysmal supraventricular tachycardia. Ann Emerg Med 1991;20:552–4.

14. Ramlakhan KP, Johnsr MR, Roos-Hesselink JW. Pregnancy and cardiovascular disease. Nat Rev Cardiol 2020;17:718–31.

15. Ruyts TPE, Roos-Hesselink JW, Hall R, et al. Heart failure in pregnant women with cardiac disease: data from the ROPAC. Heart 2014;100:231–8.

16. Salam AM, Ertekin E, van Hagen IM, et al. Atrial Fibrillation or Flutter During Pregnancy in Patients With Structural Heart Disease: Data From the ROPAC (Registry on Pregnancy and Cardiac Disease, ACC-Clin Electrophysiol 2015;1:284–92.

17. Drenthen W, Pieper PG, Roos-Hesselink JW, et al. Outcome of pregnancy in women with congenital heart disease: a literature review. J Am Coll Cardiol 2007;49:2363–11.

18. Szekely P, Szabó I, Atrial fibrillation and pregnancy. Br Med J 1961;1:1407–10.

19. Hindricks G, Potpara T, Dages N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European association for Cardio-Thoracic surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European heart rhythm association (EHRA) of the ESC. Eur Heart J 2021;42:473–498.

20. Wang Y-C, Chen C-H, Su H-Y, et al. The impact of maternal cardioversion on fetal haemodynamics. Eur J Obstet Gynecol Reprod Biol 2006;126:268–9.

21. Barnes EL, Eben F, Patterson D. Direct current cardioversion during pregnancy should be performed with facilities available for fetal monitoring and emergency caesarean section. BJOG 2002;109:1406–7.

22. Masuda K, Ishizu T, Niwa K, et al. Increased risk of thromboembolic events in adult congenital heart disease patients with atrial tachyarrhythmias. Int J Cardiol 2017;234:69–75.

23. Chang S-H, Kuo C-F, Chou I-J, et al. Outcomes associated with paroxysmal supraventricular tachycardia during pregnancy. Circulation 2017;135:616–8.

24. Filton CA, Steiner MFC, Auocut L, et al. In-uterio exposure to antihypertensive medication and neonatal and child health outcomes: a systematic review. J Hypertens 2017;35:2123–37.

25. Driver K, Chisholm CA, Darby AE, et al. Catheter ablation of arrhythmia during pregnancy. J Cardiovasc Electrophysiol 2015;26:698–702.

26. Katritsis DG, Boriani G, Cosio FG, et al. European heart rhythm association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by heart rhythm society (HRS), Asia-Pacific heart rhythm society (APHRS), and Sociedad Latinoamericana de Estimulacion cardiac y Electrosolfisica (SOLASEC). Europace 2017;19:465–511.

27. Chen G, Wang Y, Proietti R, et al. Zero-fluorosity approach for ablation of supraventricular tachycardia using the Ensite NavX system: a multicenter experience. BMC Cardiovasc Disord 2020;20:48.

28. Kozluk E, Piatkowska A, Kliszcz M, et al. Catheter ablation of cardiac arrhythmias in pregnancy without fluoroscopy: a case control retrospective study. Adv Clin Exp Med 2017;26:129–34.

29. Fink T, Sciaica V, Feickert S, et al. Outcome of cardiac tamponades in interventional electrophysiology. Europace 2020;22:1240–51.

30. Briggs G, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation. Philadelphia: Lippincott Williams & Wilkins, 2009.